Additionally, the repurposing of approved drugs targeting ITGB2, GP1BA, ACADSB and COX6B1 for the treatment of different lung cancer subtypes provides new therapeutic options, potentially leading to more effective treatments for patients with advanced lung cancer. Here, COX6B1 is linked to lung carcinoma.